// App-Quantinova.ai

3102.0 : An increase in serum choline levels to predict progression-free survival (PFS) in patients (pts) with advanced cancers receiving pembrolizumab.

Researchers

Presenter

  • Geoffrey Alan Watson

Principal Investigators

  • Wenjiang Zhang

  • Zhihui (Amy) Liu

  • Anna Spreafico

  • Aaron Richard Hansen

  • Philippe L. Bedard

  • Stephanie Lheureux

  • Albiruni Ryan Abdul Razak

  • David W. Cescon

  • Marcus O. Butler

  • Wei Xu

  • Tak Mak

  • Lillian L. Siu

  • Eric Xueyu Chen

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Tumor mutational burden

Drug/Treatment

  • Pembrolizumab

  • Choline bitartrate

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved